Oxaprozin is an effective and well tolerated non-steroidal anti-inflammatory drug (NSAID) indicated for the symptomatic treatment of several musculoskeletal conditions, including osteoarthritis and adult rheumatoid arthritis.

Oxaprozin is a propionic acid derivative which exerts its anti-inflammatory activity also through COX-independent pathways, i.e. inhibition of nuclear translocation of NF-kB and metalloproteases, also modulating the endogenous cannabinoid system.

It is also characterized by peculiar pharmacokinetic properties: its long-plasma half-like of 50-60 hours allows once-daily administration. Furthermore, its dual metabolic and elimination pathways support its good tolerability profile.

Oxaprozin’s high concentration in the synovial tissue contributes to explain its clinical efficacy, which is well documented by a large number of controlled clinical trials where this drug is favourably compared with therapeutic agents of the same class.

Helsinn acquired from Wyeth the exclusive worldwide licensing rights, excluding USA, Canada and Japan. Helsinn’s Oxaprozin was first marketed in Italy in 2000, followed by several launches in Europe and Latin America under the trademarks Dayrun®, Duraprox® and Walix®.